Cargando…
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data
INTRODUCTION: Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone a...
Autores principales: | Kim, Jiwon, Chung, Chiwook, Cho, Hyo Sin, Kim, Ho Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897553/ https://www.ncbi.nlm.nih.gov/pubmed/36735694 http://dx.doi.org/10.1371/journal.pone.0281295 |
Ejemplares similares
-
Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis
por: Chung, Chiwook, et al.
Publicado: (2022) -
Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Lee, Ju Kwang, et al.
Publicado: (2023) -
Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017) -
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
por: Song, Myung Jin, et al.
Publicado: (2020) -
Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)